OnCusp Taps Finance Veteran Kim as CFO, Signaling Major Growth Phase

PRINCETON, N.J. – May 14, 2026 – Clinical-stage biopharmaceutical company OnCusp Therapeutics has appointed Anthony Kim, a seasoned finance executive with over two decades of experience in biotechnology and capital markets, as its new Chief Financial Officer. The move is a significant strategic signal that the oncology-focused company is preparing for its next major growth phase as it advances its promising pipeline, led by a novel cancer therapy currently in human trials.

In his new role, Mr. Kim will be at the helm of OnCusp's capital markets strategy, financial planning, and investor relations. His appointment comes at a critical time for the company, which is developing a portfolio of differentiated cancer treatments and requires substantial capital to fund its ambitious clinical development programs.

A Strategic Hire for a Critical Juncture

OnCusp's leadership has made it clear that Kim's appointment is a deliberate move to bolster its financial leadership ahead of key milestones. His extensive background is seen as crucial for navigating the company's path toward significant value creation.

"Anthony's extensive experience at the intersection of biotech and capital markets makes him an ideal fit for us as we advance our pipeline and prepare for future value inflection points," said Bing Yuan, Chief Executive Officer of OnCusp Therapeutics, in a statement. "His track record of building strong investor relationships and executing complex financings will be instrumental to OnCusp's next phase of growth."

That track record is substantial. Before joining OnCusp, Kim served as a CFO Consultant for Orum Therapeutics, where he advised on U.S. capital markets strategy and public market readiness. Prior to that, as CFO of the publicly traded immuno-oncology firm Marker Therapeutics, he was instrumental in strengthening the company's financial position, leading efforts that raised over $130 million in equity financing and secured additional non-dilutive funding. His career also includes nearly two decades in investment banking at powerhouse firms like J.P. Morgan and Jefferies, where he executed strategic transactions totaling more than $30 billion.

For a clinical-stage company like OnCusp, these "value inflection points" typically refer to major clinical trial data readouts or regulatory milestones, such as the FDA Fast Track Designation the company has already received for its lead candidate. Positive results at these stages can dramatically increase a company's valuation and attract significant further investment.

Navigating a Challenging Biotech Funding Climate

The hiring of a financial heavyweight like Kim is particularly noteworthy given the current state of the biotechnology funding market. After the record highs of 2020 and 2021, the sector has faced a significant cooldown. Investors have become more cautious, and capital is harder to come by, especially for earlier-stage companies. Venture capital firms are now placing greater emphasis on proven leadership, platform differentiation, and highly disciplined capital deployment strategies.

Despite this challenging environment, oncology remains a top area of investment, particularly the "red hot" field of antibody-drug conjugates (ADCs)—the same technology underpinning OnCusp's lead program. This creates a high-stakes landscape where companies with promising assets must compete fiercely for funding. Having a CFO with deep connections to global capital markets and a proven ability to raise substantial funds is a distinct competitive advantage.

OnCusp has already demonstrated its ability to attract top-tier investors. In January 2024, the company announced an oversubscribed $100 million Series A financing round co-led by prominent life science investors Novo Holdings, OrbiMed, and F-Prime Capital. This followed a $25 million seed round in 2021, bringing its total funding since its inception to approximately $139 million. Kim's appointment is a clear move to build on this strong financial foundation and prepare for the even larger capital requirements of later-stage clinical development.

CUSP06 and the Path to Proof-of-Concept

The capital raised and future financing efforts will be directed toward OnCusp's innovative pipeline, most notably its lead candidate, CUSP06. This investigational therapy is an antibody-drug conjugate engineered to target Cadherin-6 (CDH6), a protein overexpressed on the surface of several types of cancer cells, including in ovarian and renal cancers.

ADCs are a form of targeted therapy designed to act like a guided missile, delivering a potent cancer-killing payload directly to tumor cells while minimizing damage to healthy tissue. OnCusp's CUSP06 is designed to improve upon existing ADC technologies with features aimed at increasing potency and overcoming drug resistance.

In March 2024, OnCusp initiated a first-in-human Phase 1 clinical trial for CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. The company has since reported encouraging initial data from this study and, in a significant validation of its potential, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in February 2025 for the treatment of platinum-resistant ovarian cancer—a condition with high unmet medical need.

Successfully advancing CUSP06 through clinical trials is a costly endeavor, with late-stage trials often requiring hundreds of millions of dollars. Kim's primary mandate will be to ensure OnCusp has the financial resources not only to complete these trials but also to expand its portfolio and internal capabilities.

Signaling Future Ambitions: An IPO on the Horizon?

While the immediate focus is on pipeline execution, the appointment of a CFO with Kim's specific expertise is fueling speculation about OnCusp's long-term financial strategy. His recent role advising Orum Therapeutics on "public market readiness" is a particularly strong indicator that OnCusp may be laying the groundwork for an Initial Public Offering (IPO).

For a private, clinical-stage company, going public is a common strategy to access the vast pool of capital needed to fund expensive Phase 3 trials and prepare for potential commercialization. The process is complex and requires a leader who can navigate intense regulatory scrutiny, build relationships with public market investors, and craft a compelling long-term financial narrative. Kim's background in both investment banking and as a public company CFO makes him uniquely suited for this task.

Whether the ultimate path is an IPO, a strategic sale, or another major private financing round, bringing Kim on board provides OnCusp with the expertise and optionality to pursue the most advantageous financial path forward. His arrival marks a new chapter for the company, one clearly focused on translating its scientific progress into significant financial and clinical milestones.